ADAM8 and neoplasm: In TNBC mouse models, an ectodomain antibody against ADAM8 was reported to decrease primary tumour growth, inhibit metastasis formation, and reduce the size of existing metastases, suggesting a new therapeutic approach for TNBC [65].